Vanguard Group Inc. boosted its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 4.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,203,569 shares of the company's stock after purchasing an additional 485,102 shares during the period. Vanguard Group Inc. owned about 6.00% of Doximity worth $598,159,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of DOCS. Charles Schwab Investment Management Inc. grew its holdings in Doximity by 4.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 753,001 shares of the company's stock worth $32,808,000 after acquiring an additional 31,966 shares during the last quarter. Cerity Partners LLC grew its stake in shares of Doximity by 21.4% in the third quarter. Cerity Partners LLC now owns 49,876 shares of the company's stock worth $2,173,000 after purchasing an additional 8,781 shares during the last quarter. MetLife Investment Management LLC increased its holdings in Doximity by 0.6% during the 3rd quarter. MetLife Investment Management LLC now owns 65,064 shares of the company's stock valued at $2,835,000 after purchasing an additional 363 shares during the period. Verition Fund Management LLC raised its position in Doximity by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 42,812 shares of the company's stock valued at $1,865,000 after purchasing an additional 3,088 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new stake in Doximity in the 3rd quarter worth approximately $137,000. Institutional investors own 87.19% of the company's stock.
Doximity Price Performance
NASDAQ DOCS traded up $1.24 during mid-day trading on Wednesday, reaching $57.96. The stock had a trading volume of 1,819,929 shares, compared to its average volume of 1,940,779. The stock has a market cap of $10.82 billion, a PE ratio of 57.96, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $85.21. The company has a fifty day moving average price of $65.59 and a 200 day moving average price of $54.81.
Insider Activity at Doximity
In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. This represents a 75.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 37.40% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. Stephens started coverage on Doximity in a report on Friday, December 20th. They set an "equal weight" rating and a $55.00 target price for the company. Mizuho raised their target price on shares of Doximity from $55.00 to $65.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Doximity in a research note on Friday, February 7th. Canaccord Genuity Group increased their price target on shares of Doximity from $60.00 to $71.00 and gave the stock a "hold" rating in a research note on Friday, February 7th. Finally, The Goldman Sachs Group upped their target price on Doximity from $58.00 to $80.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Doximity has a consensus rating of "Moderate Buy" and a consensus target price of $64.22.
Check Out Our Latest Stock Analysis on Doximity
About Doximity
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
See Also
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
